Blair William & Co. IL Sells 105,569 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• Blair William & Co. IL reduced its position in TransMedics Group by 58.5%, selling over 105,000 shares during the first quarter, while still holding nearly 75,000 shares worth approximately $5 million.
• TransMedics Group reported $0.92 earnings per share for the last quarter, significantly exceeding analyst estimates of $0.48, with a revenue increase of 37.7% year-over-year.
• Multiple analysts have upgraded their ratings and price targets for TransMedics Group, with current consensus and price target reflecting a Moderate Buy rating and an average target price of $123.00.

Blair William & Co. IL lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 58.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 74,995 shares of the company's stock after selling 105,569 shares during the quarter. Blair William & Co. IL owned approximately 0.22% of TransMedics Group worth $5,046,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in TMDX. Braidwell LP bought a new stake in shares of TransMedics Group during the fourth quarter worth approximately $57,493,000. Mackenzie Financial Corp lifted its stake in shares of TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after purchasing an additional 349,403 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after purchasing an additional 253,624 shares during the last quarter. FIL Ltd grew its stake in shares of TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after purchasing an additional 218,961 shares during the period. Finally, Wasatch Advisors LP increased its holdings in TransMedics Group by 83.3% in the fourth quarter. Wasatch Advisors LP now owns 441,354 shares of the company's stock valued at $27,518,000 after purchasing an additional 200,603 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Down 1.3%

Shares of NASDAQ:TMDX traded down $1.55 during mid-day trading on Friday, reaching $114.50. 731,219 shares of the stock were exchanged, compared to its average volume of 1,403,726. The stock's 50 day simple moving average is $123.84 and its 200-day simple moving average is $97.41. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a market cap of $3.90 billion, a P/E ratio of 59.33 and a beta of 2.09. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. During the same period in the previous year, the business earned $0.35 EPS. The company's revenue was up 37.7% compared to the same quarter last year. As a group, equities research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of recent analyst reports. Piper Sandler restated an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Oppenheimer increased their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Morgan Stanley raised their price objective on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $123.00.

Insider Activity at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the transaction, the director owned 2,866 shares of the company's stock, valued at $362,405.70. This trade represents a 63.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,418 shares of company stock valued at $818,833. Insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.